The Pharmacoepidemiology of Psychiatric Medications

Textbook in Psychiatric Epidemiology: Third Edition

Volumn , Issue , 2011, Pages 155-165

  Wang, Philip S ^a   Brookhart, Alan M ^b   Ulbricht, Christine ^a   Schneeweiss, Sebastian ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866731689     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470976739.ch10     Document Type: Chapter

References (66)

1. Schatzberg, A. and Nemeroff, C. (2006) Essentials of Clinical Psychopharmacology, 2nd edn. American Psychiatric Publishing, Inc.
2. Leucht, S., Pitschel-Walz, G., Abraham, D. et al. (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res., 35, 51-68.
3. Wang, P.S., West, J.C., Tanielian, T. et al. (2000) Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr. Bull., 26, 451-457.
4. Lieberman, J.A., Stroup, T.S., McEvoy, J.P. et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 353, 1209-1223.
5. Honer, W.G., Thornton, A.E., Chen, E.Y. et al. (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med., 354, 472-482.
6. U.S. Congressional Budget Office (2007) Research on the Comparative Effectiveness of Medical Treatments: Issues and Options for an Expanded Federal Role, Congressional Budget Office, Washington, DC. December.
7. Polinski, J.M., Wang, P.S., and Fischer, M.A. (2007) Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Aff., 26, 750-760.
8. Fischer,M.A., Servi, A.D., Polinski, J.M. et al. (2007) Restrictions on antidepressant medications for children: a review of medicaid policy. Psychiatr. Serv., 58, 135-138.
9. Wang, P.S., Aguilar-Gaxiola, S., Alonso, J., et al. The WHO World Mental Health Survey Consortium (2007) Worldwide use of mental health services for anxiety, mood, and substance disorders: results from 17 countries in the WHO World Mental Health (WMH) surveys. Lancet, 370, 841-850.
10. Wang, P.S., Demler, O., Olfson, M. et al. (2006) Changing profiles of service sectors used for mental health care in the United States. Am. J. Psychiatry, 163, 1187-1198.
11. Kessler, R.C., Demler, O., Frank, R.G. et al. (2005) Prevalence and treatment of mental disorders, 1990 to 2003.N. Engl. J. Med., 352, 2515-2523.
12. Kessler, R.C., Berglund, P., Borges, G. et al. (2005) Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001- 2003. J. Am. Med. Assoc., 293, 2487-2495.
13. Strom, B.L. (1994) What is pharmacoepidemiology? in Pharmacoepidemiology, 2nd edn (ed B.L. Strom), John Wiley & Sons, Inc., New York, pp. 3-13.
14. McBride, W.G. (1961) Thalidomide and congenital abnormalities. Lancet, ii, 1358.
15. Wilholm, B.E., Onsson, S., Moore, N., et al. (1994) Spontaneous reporting system outside the United States, in Pharmacoepidemiology, 2nd edn (ed. B.L. Strom), John Wiley & Sons, Inc., New York, pp. 139-155.
16. Baum, C., Kweder, S.L., and Anello, C. (1994) The spontaneous reporting system in the United States, in Pharmacoepidemiology, 2nd edn (ed B.L. Strom), John Wiley & Sons, Inc., New York, pp. 125-137.
17. Mattison, N., and Richard, B.W. (1987) Postapproval research requested by the FDA at the time of NCE approval, 1970-1984. Drug Inf. J., 21, 309-329.
18. Cole, J.O. (1988) Where are those new antidepressants we were promised? Arch. Gen. Psychiatry, 45, 193-197.
19. Morris, H.H., and Estes,M. (1987) Traveler's amnesia: transient global amnesia secondary to triazolam. J. Am. Med. Assoc., 258, 945-946.
20. Maclure, M. (1991) The case-crossover design: a method for studying transient effects of the risk of acute events. Am. J. Epidemiol., 113, 144-153.
21. Suissa, S. (1995) The case-time-control design. Epidemiology, 6, 248-253.
22. Wang, P.S., Schneeweiss, S., Glynn, R.J. et al. (2004) Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann. Epidemiol., 14, 296-303.
23. Schneeweiss, S., Maclure, M., Walker, A.M. et al. (2001) On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy, 55, 97-109.
24. Gold, M.R., Siegel, J.E., and Russell, L.B. (1996) Cost-Effectiveness in Health and Medicine, Oxford University Press, New York.
25. Eddy, D.M. (2007) Linking electronic medical records to large-scale simulation models: can we put rapid learning on turbo? Health Aff., 26, w125-w136.
26. Rosenbaum, P.R., and Rubin, D.B. (1983) Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. J. R. Stat. Soc. B, 45, 212-218.
27. Schneeweiss, S. (2007) Developments in postmarketing comparative effectiveness research. Clin. Pharmacol. Ther., 82, 143-156.
28. Seeger, J.D., Kurth, T., and Walker, A.M. (2007) Use of propensity score technique to account for exposure related covariates. Med. Care, 45, S143-S148.
29. Schneeweiss, S., Patrick, A.R., Stürmer, T. et al. (2007) Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med. Care, 45, S131-S142.
30. Stürmer, T., Glynn, R.J., Rothman, K.J. et al. (2007) Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med. Care, 45, S158-S165.
31. Brookhart, M.A., Rassen, J.A., Wang, P.S. et al. (2007) Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med. Care, 45, S116-S122.
32. Strom, B.L. (1994b) How should one perform pharmacoepidemiology studies?: Choosing among the available alternatives, in Pharmacoepidemiology, 2nd edn (ed B.L. Strom), John Wiley & Sons, Inc., New York, pp. 337-350.
33. Bright, R.A., Avorn, J., and Everitt, D.E. (1989) Medicaid data as a resource for epidemiologic studies: strengths and limitations. J. Clin. Epidimiol., 42, 937-945.
34. Lessler, J.T., and Harris, B.S.H. (1984) Medicaid Data as a Source for Postmarketing Surveillance Information, Final Report, Research Triangle Institute, Research Triangle Park, NC.
35. Roos, L.L., Sharp, S.M., and Cohen, M.M. (1991) Comparing clinical information with claims data: some similarities and differences. J. Clin. Epidemiol., 44, 881-888.
36. Trivedi, M.H., Fava, M., Wisniewski, S.R. et al. (2006) Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med., 354, 1243-1252.
37. Sachs, G.S., Nierenberg, A.A., Calabrese, J.R. et al. (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med., 356, 1711-1722.
38. March, J.S., Silva, S.G., Compton, S. et al. (2005) The case for practical clinical trials in psychiatry. Am. J. Psychiatry, 162, 836-846.
39. McGrath, P.J., Kahn, A.Y., Trivedi,M.H. et al. (2008) Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J. Clin. Psychiatry, 69, 1847-1855.
40. Dennehy, E.B., Bauer, M.S., Perlis, R.H. et al. (2007) Concordance with treatment guidelines for bipolar disorder: data from the Systematic Treatment Enhancement Program for Bipolar Disorder. Psychopharmacol. Bull., 40, 72-84.
41. US Food and Drug Administration (2004) Center for Drug Evaluation and Research: FDA Public Health Advisory: Worsening Depression and Suicidality in Patients Being Treated with Antidepressant Medications, March 22, 2004. Available at: http://www.fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInforma tionforPatientsandProviders/DrugSafetyInformation forHeathcareProfessionals/PublicHealthAdvisories/ ucm161696.htm (accessed 29 November 2010).
42. US Food and Drug Administration (2004) Summary Minutes of the September 13-14, 2004 Center for Drug Evaluation and Research Pharmachopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. Available at: http://www.fda.gov/ohrms/dockets/ac/04/minutes/ 2004-4065M1_Final.htm. (accessed 27 September 2010).
43. Jick, H., Kaye, J., and Jick, S. (2004) Antidepressants and the risk of suicidal behaviors. J. Am.Med. Assoc., 292, 338-343.
44. Martinez, C., Rietbrock, S., Wise, L. et al. (2005) Antidepressant treatment and the risk of fatal andnon-fatal self-harm in the first episode of depression. Br. Med. J., 330, 389.
45. Simon, G.E., Savarino, J., Operskalski, B. et al. (2006) Suicide risk during antidepressant treatment. Am. J. Psychiatry, 163, 41-47.
46. Olfson, M., and Marcus, S.C. (2008) A case-control study of antidepressants and attempted suicide during early phase treatment of major depressive episodes. J. Clin. Psychiatry, 69, 425-432.
47. US Food and Drug Administration (2006) Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf. (accessed 27 September 2010).
48. US Food and Drug Administration (2005) FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandPro viders/DrugSafetyInformationforHeathcareProfession als/PublicHealthAdvisories/ucm053171.htm (accessed 29 November 2010).
49. Wang, P.S., Schneeweiss, S., Avorn, J. et al. (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med., 353, 2335-2341.
50. Schneeweiss, S., Setoguchi, S., Brookhart, A. et al. (2007) Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Can. Med. Assoc. J., 176, 627-632.
51. Gill, S.S., Bronskill, S.E., Normand, S.L. et al. (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann. Intern. Med., 146, 775-786.
52. US Food and Drug Administration (2008) FDA alert. Cent. Drug Eval. Res., Available at: http://www.fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm110212.htm (accessed 29 November 2010).
53. Collins, J.C., andMcFarland, B.H. (2008) Divalproex, lithium and suicide among Medicaid patients with bipolar disorders. J. Affect Disord., 107, 23-28.
54. Olfson, M., Blanco, C., Liu, L. et al. (2006) National trends in outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry, 63, 679-685.
55. Moreno, C., Laje, G., Blanco, C. et al. (2007) National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch. Gen. Psychiatry, 64, 1032-1039.
56. Wang, P.S., Lane,M., Olfson, M. et al. (2005) Twelvemonth use of mental health services in the United States. Arch. Gen. Psychiatry, 62, 629-640.
57. Wang, P.S., Schneeweiss, S., Brookhart, M.A. et al. (2005) Suboptimal antidepressant use in the elderly. J. Clin. Psychopharmacol., 25, 118-126.
58. Simon, G.E., Katon, W.J., VonKorff,M. et al. (2001a) Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am. J. Psychiatry, 158, 1638-1644.
59. Simon, G.E., Manning, W.G., Katzelnick, D.J. et al. (2001) Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen. Psychiatry, 58, 181-187.
60. Schoenbaum, M., Unutzer, J., Sherbourne, C. et al. (2001) Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. J. Am.Med. Assoc., 286, 1325-1330.
61. Wang, P.S., Patrick, A.R., Avorn, J. et al. (2006) The costs and benefits of enhanced depression care to employers. Arch. Gen. Psychiatry, 63, 1345-1353.
62. Wang, P.S., Patrick, A.R., Dormuth, C. et al. (2008) The impact of cost-sharing on antidepressant use among older adults in British Columbia. Psychiatr. Serv., 59, 377-383.
63. US Food and Drug Administration Amendments Act of 2007. Public Law 110-85, September (2007). Title IX, Section 905.
64. Clancy, C.M. (2006) Getting to 'smart' health care. Health Aff., 25 (6), w589-w592.
65. Wilensky, G.R. (2006) Developing a center for comparative effectiveness information. Health Aff., 25, w572-w585.
66. US Senate (2008) Comparative Effectiveness Research Act of 2008. United States Senate Bill S. 3408, July 31.